NeuroPace Announces Upcoming Oral Presentation of Data from the Post-Approval Study of the RNS System at the American Academy of Neurology 2025 Annual Meeting Being Held April 5th – 9th

Core Insights - NeuroPace, Inc. is focused on transforming the lives of individuals with epilepsy through innovative medical devices [3] - The company announced that an abstract from its Post-approval Study of the RNS System will be presented at the AAN 2025 Annual Meeting [1] Presentation Details - The presentation titled "Multicenter Post-approval Study of the RNS System in Focal Epilepsy" will be delivered by Dr. Dawn Eliashiv [2] - The session is scheduled for April 7, 2025, at 5:06 PM PT [2] Company Overview - NeuroPace is based in Mountain View, California, and specializes in developing the RNS System, which is the first commercially available brain-responsive platform for epilepsy treatment [3] - The RNS System aims to provide personalized, real-time treatment at the source of seizures, potentially improving care for patients with drug-resistant epilepsy [3]